CASE REPORT

Robotic total gastrectomy with thrombectomy and portal vein reconstruction for gastric cancer and portal vein tumor thrombus

Masaaki Yamamoto, Takeshi Omori*, Naoki Shinno, Hisashi Hara, Yosuke Mukai, Takahito Sugase, Tomohira Takeoka, Kei Asukai, Takashi Kanemura, Nozomu Nakai, Shinichiro Hasegawa, Keijiro Sugimura, Hiroyumi Akita, Naotsugu Haraguchi, Junichi Nishimura, Hiroshi Wada, Hidenori Takahashi, Chu Matsuda, Masayoshi Yasui, Hiroshi Miyata and Masayuki Ohue

Abstract

Background: Gastric cancer with portal vein tumor thrombus (PVTT) is poor prognosis, and the treatment remains challenging. Regarding surgery, there are only reports of highly invasive laparotomy. We report some techniques of the completely robotic total gastrectomy with thrombectomy and portal vein reconstruction for the patient with gastric cancer and PVTT for the first time.

Case presentation: A 79-year-old man was diagnosed with a 5-cm gastric cancer on the side of the lesser curvature from the middle of the gastric body to the cardia. Computed tomography revealed a massive PVTT extending from the left gastric vein to the portal trunk (28 x 16 mm). There were no other distant metastases. After 3 cycles of the chemotherapy, the PVTT shrank to 19 x 12 mm. After obtaining informed consent from the patient, robotic total gastrectomy with regional lymphadenectomy and thrombectomy were performed for the patient with gastric cancer and PVTT for the first time.

After PVTT identification, the portal trunk was clamped above and below the tumor thrombus with vascular clips. The membrane on the anterior wall of the portal trunk around the PVTT was carefully incised with da Vinci Scissors. The tumor thrombus was completely enucleated without separation. The incised part of the portal trunk was reconstructed with continuous 5-0 synthetic monofilament nonabsorbable polypropylene sutures. After removing the vascular clamps, we made sure there was no leakage from the portal vein and no tumor thrombus remnants with intraoperative ultrasonography. Robotic total gastrectomy with lymphadenectomy and Roux-en-Y reconstruction were performed. The patient was discharged without complications. The patient has remained alive for 30 months after surgery.

Conclusions: Robotic total gastrectomy with thrombectomy and portal vein reconstruction is a safe, minimally invasive, and precise surgery. It may contribute to improved prognosis of gastric cancer with PVTT when combined with chemotherapy.
Background
Gastric cancer with portal vein tumor thrombus (PVTT) have been reported to have poor prognosis [1–3]. The median survival of gastric cancer patients with PVTT is 5.4 months, and the 5-year survival rate is less than 10% [3]. Several studies have shown that the prognosis of patients with gastric cancer and PVTT are improved after gastrectomy [2–4]. However, there are no reports about patients with gastric cancer and PVTT who undergo laparoscopic or robotic gastrectomy. We reported the first case of a patient with gastric cancer and PVTT who underwent robotic radical total gastrectomy with thrombectomy and portal vein reconstruction after chemotherapy.

Case presentation
A 79-year-old man presented with upper abdominal pain. He was diagnosed with gastric cancer and referred to our hospital. Gastrointestinal endoscopy revealed an elevated tumor on the side of the lesser curvature, from the middle of the gastric body to the cardia. The length was approximately 5 cm (Fig. 1A, B). Pathological examination of a biopsy specimen revealed moderately and poorly differentiated adenocarcinoma and human epidermal growth factor receptor-2 (HER-2) positivity. Enhanced computed tomography (CT) revealed a massive PVTT extending from the left gastric vein to the portal trunk (size: 28.7 x 16.9 mm) (Fig. 1C). There were no other distant metastases. Serum carcinoembryonic antigen and alpha-fetoprotein levels were high, 108 ng/mL and 36 ng/mL, respectively. Carbohydrate antigen 19-9 levels were normal. The patient had no liver diseases.

**Fig. 1** Gastrointestinal endoscopy revealed an elevated tumor on the side of the lesser curvature, from the middle of the gastric body to the cardia. The length of the tumor was approximately 5 cm before chemotherapy (A, B). Computed tomography revealed portal vein tumor thrombus (PVTT) (C). After chemotherapy, the primary gastric lesion flattened and the PVTT shrank (D–F). Arrowheads show PVTT (C, F). Positron emission tomography only showed abnormal uptake in the primary gastric lesion and PVTT (G, H)
The treatment regimen mainly consisted of chemotherapy: capecitabine (3000 mg/body/day, oral, days 1–14, followed by 7 days of rest), oxaliplatin (130 mg/m², intravenous, day 1), and trastuzumab (initial dose 8 mg/kg, subsequent doses 6 mg/kg, intravenous, day 1). After 3 cycles of the regimen, the primary gastric lesion was flattened and the PVTT shrank to 19.7 x 12.0 mm (Fig. 1D–F). Positron emission tomography (PET) revealed abnormal uptake only in the primary gastric lesion and PVTT (Fig. 1G, H). The therapeutic effect was evaluated as partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1[5]. Since the patient experienced grade 3 anorexia and diarrhea based on the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 during the chemotherapy, it was hard for him to continue with this chemotherapy regimen. Therefore, after obtaining informed consent from the patient, robotic total gastrectomy with regional lymphadenectomy and thrombectomy was performed after the three courses of chemotherapy.

**Operative technique**

We used the da Vinci Xi Surgical System (Intuitive Surgical, Inc., CA, USA). Under general anesthesia, the patient was positioned in a head-up tilt position (15°). A 3-cm incision was made at the umbilicus and a wound retractor was placed. The first port (8 mm) for the camera was inserted through the wound retractor (Hakko Co., Ltd., Tokyo, Japan). Five additional ports were inserted as follows: 12 mm port for the robot in the right hypochondrium, 12 mm port for the assistant surgeon in the right upper abdomen between the 12 mm port for robot and the umbilicus, 8 mm port for the robot in the left hypochondrium, 8 mm port for the robot in the left upper abdomen between the 8 mm port for the robot in the hypochondrium and the umbilicus, and 5 mm port for the assistant surgeon (AirSeal®, ConMed, Largo, FL, USA) in the epigastric region. The first, second, third, and fourth robotic arms were docked on the 12-mm right hypochondrium, camera, left upper, and left hypochondrium ports, respectively (Fig. 2). Peritoneal and liver metastases were not detected. Intraoperative cytodiagnosis of ascites fluid was negative. Lymph node dissection was performed according to the criteria in the gastric cancer guidelines of the Japanese Gastric Cancer Association [6, 7].

We firstly start to perform lymphadenectomy at the lymph nodes along the distal portion of the stomach (no. 4sb, 4d, 5, 6) followed by resect duodenum. Next, the lymphadenectomy is performed at the left side suprapancreatic nodes (no. 7, 9, 11p, 11d). The dissection of the right side suprapancreatic nodes (no. 8a, 12a) are performed at the time of the thrombectomy.

Regarding thrombectomy, the common hepatic artery, proper hepatic artery, gastroduodenal artery, PV, superior mesenteric vein, and left gastric vein (LGV) were definitively identified and labeled with vascular tape (Fig. 3A). The precise extent of the PVTT, from the LGV...
to the portal trunk, was identified with intraoperative ultrasonography (Fig. 3B, C). After PVTT identification, the portal trunk was clamped above and below the tumor thrombus with vascular clips (Fig. 3D). The membrane on the anterior wall of the portal trunk around the LGV bifurcation was carefully incised with da Vinci Scissors. The incision was gradually extended along the tumor thrombus (Fig. 3E, F). The tumor thrombus was completely enucleated without separation (Fig. 3G, H). The incised part of the portal trunk was reconstructed with continuous 5-0 synthetic monofilament nonabsorbable polypropylene sutures (Fig. 3I). After removing the vascular clamps, we made sure there was no leakage from the PV and no tumor thrombus remnants with intraoperative ultrasonography (Fig. 3J).

After the thrombectomy and PV reconstruction, the lymphadenectomy of the paracardial nodes (no. 1, 2, 3, 4sa) are performed and resect the esophagus. Total gastrectomy and D2 lymphadenectomy are the same as previously described [8, 9]. After the resection of the stomach, it was removed from the abdomen along with the tumor thrombus.

Roux-en-Y anastomosis was performed. A side-to-side jejunojejunal anastomosis was created approximately 30 cm from the ligament of Treitz with the linear stapler. The entry hole for the jejunojejunal anastomosis was closed with a continuous 4-0 synthetic monofilament barbed suture. A side-to-side esophagojejunal anastomosis was created approximately 35 cm from the jejunojejunal anastomosis with the linear stapler. The entry hole of the esophagojejunal anastomosis was closed with the linear stapler (Fig. 3K, L). The total operative time and console time were 418 and 398 min, respectively. The estimated blood loss was less than 5 ml. The operation was performed by a surgeon (T.O.) who had experienced more than 100 robotic gastrectomies.

Clinical outcomes
The patient resumed oral ingestion of water on postoperative day (POD) 2 and porridge on POD 3. Follow-up CT showed no PV obstruction. The drain tube was removed on POD 4. There were no complications. The patient was discharged on POD 9.

Pathological examination revealed poorly differentiated adenocarcinoma (solid type) with invasion of the subserosa, perigastric lymph node metastases, and PVTT (Fig. 4A, B). The effectiveness of preoperative chemotherapy was pathologically diagnosed as Grade 2a, which means viable tumor cells remained in 1/10
to less than 1/3 of the neoplastic area, according to the tumor response criteria in the Japanese Classification of Gastric Carcinoma [10, 11]. PVTT appeared resolved on CT (Fig. 5). The patient had received trastuzumab, and no recurrence had been observed for 14 months after surgery. However, the lesion suspected of recurrence was detected at the dorsal side of anastomosis along the hemiazygous vein by CT and PET on the 14 months after surgery. Therefore, nanoparticle albumin-bound paclitaxel (nab-PTX) plus ramucirumab were given as the second regimen (nab-PTX, 80 mg/m²/day, intravenously, day 1, 8, 15; ramucirumab, 8 mg/m²/day, intravenously, day 1, 15, followed by 7 days' rest). He has been received nab-PTX plus ramucirumab and has remained alive for 30 months after surgery.

Discussion and conclusions
This is the first report about a patient with gastric cancer and PVTT who underwent robotic gastrectomy with thrombectomy and PV reconstruction. The operation was successfully performed as planned. We hereby report some techniques for robotic surgery in patients with gastric cancer and PVTT.

Robotic surgery has many advantages for gastrectomy with thrombectomy compared with laparotomy or laparoscopy [12–16]. First, since the robot provides highly magnified 3-dimensional (3D) high-definition vision, which displays 3D stereoscopic images, surgeons have a better 3D view. Second, since the multiple articulations of the endo-wrist can allow the instruments to curve over an acutely angled and deep area, the robot is able to approach the area and contribute to precise lymphadenectomy and thrombectomy. Third, tremor reduction with robot can also achieve more precise and safer surgery than laparotomy or laparoscopy. Moreover, a minimally invasive and precise procedure with the robot may contribute to fewer complications and shorter hospital stays [16–19].

In general, gastric cancer with PVTT is considered advanced. The main treatment for gastric cancer with PVTT is chemotherapy. However, several recent reports have shown that surgery improves the prognosis of patients with gastric cancer and PVTT [2–4, 20, 21]. Moreover, neoadjuvant chemotherapy (NAC) was reported to play an important role in reducing the size of the tumor. Nakao et al. and Orii et al. reported that NAC for patients with gastric cancer and PVTT induces the disappearance of PVTT and makes radical surgery possible [3, 4]. In two patients, 3 to 4 cycles of a regimen containing S-1 plus cisplatin was given as NAC. In the present case, the patient received NAC consisting of capecitabine, oxaliplatin, and
trastuzumab. The primary tumor and PVTT decreased in size, corresponding to PR.

Several reports have described patients who received chemotherapy consisting of S-1, S-1 plus paclitaxel, 5-fluorouracil (5-FU), or 5-FU plus cisplatin after NAC [3, 4, 20, 21]. In the present case, the patient received trastuzumab alone after surgery [3, 4, 20, 21]. In the present case, the patient received trastuzumab after surgery for 44–156 months after surgery, there have no reports about patients with PVTT who received trastuzumab after surgery [3, 4, 20, 21]. In the present case, the patient received postoperative chemotherapy and had no recurrences until 14 months after surgery. After recurrence, he received second-line chemotherapy and has remained alive 30 months after surgery. However, the most appropriate timing of surgical intervention or chemotherapy and chemotherapy duration before or after surgery have not been established yet. Although the main treatment for gastric cancer with PVTT is chemotherapy, the surgical intervention may be considered when it is considered that the chemotherapy is effective and radical resection is possible. Robotic surgery may contribute to be the radical resection because of minimally invasive and precise surgery. More investigation is warranted.

Abbreviations
PVTT: Portal vein tumor thrombus; HER-2: Human epidermal growth factor receptor-2; CT: Computed tomography; PET: Positron emission tomography; PR: Partial response; RECIST: Response Evaluation Criteria in Solid Tumors; CTCAE: Common Terminology Criteria for Adverse Events; LGV: Left gastric vein; POD: Postoperative day; 3D: 3-Dimensional; NAC: Neoadjuvant chemotherapy; S-FU: 5-Fluorouracil.

Acknowledgments
Not applicable.

Authors’ contributions
All authors were involved in the preparation of this manuscript. TO, NS, and HW participated in the surgery. MY, TO, NS, and HH examined the patient for outpatient chemotherapy. MY wrote the manuscript. YM, TS, KT, TK, NN, SH, KS, HA, NN, JN, HT, CM, MY, HM, and MO revised the manuscript. The authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The material supporting the conclusion of this review has been included within the article.

Declarations
Ethics approval and consent to participate
The collection of patient data was approved by the local ethics committee (#20247).

Consent for publication
Written informed consent for publication was obtained from the patient.

Competing interests
The authors declare that they have no competing interests.

Received: 12 November 2021 Accepted: 2 February 2022
Published online: 16 February 2022

References
1. Tanaka A, Takeda R, Mukaihara S, Hayakawa K, Takasu K, Terajima H, et al. Tumor thrombi in the portal vein system originating from gastrointestinal tract cancer. J Gastroenterol. 2002;37:220–8.
2. Sato S, Nagai E, Taki Y, Watanabe M, Takahashi M, Kyo_den Y, et al. A long-surviving case of gastric cancer with main portal vein tumor thrombus after surgical resection and postoperative S-1 therapy. Clin J Gastroenterol. 2016;9:233–7.
3. Oni T, Karasawa Y, Kitahara H, Yoshimura M, Okumura M. Long-term survival after sequential chemotherapy and surgery for advanced gastric cancer. Int J Surg Case Rep. 2013;4:976–80.
4. Nakao S, Nakata B, Tendo M, Kuroda K, Hori T, Inaba M, et al. Salvage surgery after chemotherapy with S-1 plus cisplatin for α-fetoprotein-producing gastric cancer with a portal vein tumor thrombus: a case report. BMJ. Surg. 2015;15(11). https://doi.org/10.1186/1477-2462-15-5.
5. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
6. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.
7. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1–21.
8. Hamabe A, Omi_T, Tanaka K, Nishida T. Comparison of long-term results between laparoscopy-assisted gastrectomy and open gastrectomy with D2 lymph node dissection for advanced gastric cancer. Surg Endosc. 2012;26(6):1702–9. https://doi.org/10.1007/s00464-011-2096-0.
9. Omi_T, Yamamoto K, Hara H, Shinno N, Yamamoto M, Sugimura K, et al. A randomized controlled trial of single-port versus multi-port laparoscopic distal gastrectomy for gastric cancer. Surg Endosc. 2012;26(6):1702–9. https://doi.org/10.1007/s00464-011-2096-0.
10. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
11. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, the. 15th ed. Tokyo: Kanehara shuppan; 2017.
12. Anderson C, Ellenhorn J, Hellan M, Piggazi A. Pilot series of robot-assisted laparoscopic subtotal gastrectomy with extended lymphadenectomy for gastric cancer. Surg Endosc. 2007;21:1662–6.
13. Cadiree GB, Himpeens J, Germay O, Lizzava R, Degueilvre M, Vandromme J, et al. Feasibility of robotic laparoscopic surgery: 146 cases. World J Surg. 2001;25:1467–77.
14. Lanfranco AR, Castellanos AE, Desai JP, Meyers WC. Robotic surgery: a current perspective. Ann Surg. 2004;239(4):14–21.
15. Patriti A, Ceccarelli G, Bellochi R, Bartoli A, Spaziani A, Di Zitti L, et al. Robot-assisted laparoscopic total and partial gastric resection with D2 lymph node dissection for adenocarcinoma. Surg Endosc. 2008;22:2753–60.
16. Kim MC, Heo GL, Jung JS. Robotic gastrectomy for gastric cancer: surgical techniques and clinical merits. Surg Endosc. 2010;24:610–5.
17. Suda K, Man MI, Ishida Y, Kawamura Y, Satoh Y, Uyama I. Potential advantages of robotic radical gastrectomy for gastric adenocarcinoma in comparison with conventional laparoscopic approach: a single institutional retrospective comparative cohort study. Surg Endosc. 2015;29:673–85.
18. Uyama I, Kanaya S, Ishida Y, Inaba K, Suda K, Satoh S. Novel integrated robotic approach for suprapancreatic D2 nodal dissection for treating gastric cancer: technique and initial experience. World J Surg. 2012;36:331–7.
19. Hur H, Kim JY, Cho YK, Han SU. Technical feasibility of robot-sewn anastomosis in robotic surgery for gastric cancer. J Laparoendosc Adv Surg Tech A. 2010;20:693–7.
20. Azuma M, Suzuki S, Sakaguchi T, Ota S, Inaba K, Baba S, et al. Successful surgical resection of synchronous liver metastasis with portal tumor thrombus from alpha-fetoprotein-producing gastric cancer without.
recurrence more than 5 years after surgery: report of a case. Jpn J Gastroenterol Surg. 2005;38:1301–5.

21. Sugawara Y, Konishi T, Hiraishi M, Ishizaki Y, Makuuchi M. Portal tumor thrombi due to gastric cancer. Hepatogastroenterology. 1996;43(10):1000–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.